Research programme: osteoporosis therapeutics - TakedaAlternative Names: TAK-075
Latest Information Update: 16 Jul 2016
At a glance
- Originator Takeda
- Mechanism of Action Calcium-sensing receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoporosis in Japan (PO)
- 31 Mar 2011 Preclinical trials in Osteoporosis in Japan (PO)